Authors
Loading...
The study shows that targeting BRD9 and IRF8 improves outcomes in KMT2A AML, suggesting new treatment strategies against MEN1 resistance.
Daniela V. Wenge (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: